Market Closed -
Nasdaq
04:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
26.38
USD
|
+0.27%
|
|
-8.31%
|
-24.41%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,099
|
2,358
|
-
|
-
|
Enterprise Value (EV)
1 |
4,583
|
3,934
|
3,764
|
3,567
|
P/E ratio
|
-873
x
|
-28.7
x
|
36.5
x
|
18.8
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1
x
|
0.82
x
|
0.78
x
|
0.74
x
|
EV / Revenue
|
1.47
x
|
1.36
x
|
1.25
x
|
1.13
x
|
EV / EBITDA
|
17.1
x
|
15.6
x
|
10.1
x
|
8.73
x
|
EV / FCF
|
36.1
x
|
-296
x
|
23
x
|
16.9
x
|
FCF Yield
|
2.77%
|
-0.34%
|
4.34%
|
5.9%
|
Price to Book
|
1.78
x
|
1.49
x
|
1.25
x
|
1.13
x
|
Nbr of stocks (in thousands)
|
88,800
|
89,374
|
-
|
-
|
Reference price
2 |
34.90
|
26.38
|
26.38
|
26.38
|
Announcement Date
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,109
|
2,890
|
3,024
|
3,169
|
EBITDA
1 |
-
|
267.3
|
252.8
|
372.3
|
408.4
|
EBIT
1 |
-
|
170.9
|
212.1
|
328.9
|
357.7
|
Operating Margin
|
-
|
5.5%
|
7.34%
|
10.88%
|
11.29%
|
Earnings before Tax (EBT)
1 |
237
|
1.1
|
-131
|
37.85
|
113.9
|
Net income
1 |
192.9
|
-3.4
|
-57
|
59
|
114
|
Net margin
|
-
|
-0.11%
|
-1.97%
|
1.95%
|
3.6%
|
EPS
2 |
-
|
-0.0400
|
-0.9200
|
0.7233
|
1.400
|
Free Cash Flow
1 |
-
|
127.1
|
-13.31
|
163.5
|
210.4
|
FCF margin
|
-
|
4.09%
|
-0.46%
|
5.41%
|
6.64%
|
FCF Conversion (EBITDA)
|
-
|
47.55%
|
-
|
43.93%
|
51.53%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
277.19%
|
184.59%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/15/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
793
|
776.4
|
775.4
|
662.1
|
718.6
|
741.2
|
760.8
|
753
|
EBITDA
1 |
72.5
|
70.5
|
67.2
|
29.5
|
51.92
|
76.17
|
93.76
|
71.35
|
EBIT
1 |
63
|
45.9
|
43.3
|
7.6
|
35.61
|
55.31
|
74.84
|
54.1
|
Operating Margin
|
7.94%
|
5.91%
|
5.58%
|
1.15%
|
4.95%
|
7.46%
|
9.84%
|
7.18%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-41
|
-77.5
|
-32.97
|
1.875
|
20.56
|
5.017
|
Net income
1 |
28.3
|
-13.1
|
-36
|
-102.8
|
-
|
-
|
-
|
-
|
Net margin
|
3.57%
|
-1.69%
|
-4.64%
|
-15.53%
|
-
|
-
|
-
|
-
|
EPS
2 |
0.3200
|
-0.1500
|
-0.4100
|
-1.150
|
-0.2300
|
0.0300
|
0.1650
|
0.0400
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/14/23
|
11/13/23
|
3/11/24
|
5/13/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
1,483
|
1,576
|
1,407
|
1,209
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
5.55
x
|
6.235
x
|
3.778
x
|
2.96
x
|
Free Cash Flow
1 |
-
|
127
|
-13.3
|
164
|
210
|
ROE (net income / shareholders' equity)
|
-
|
4.9%
|
3.94%
|
8.7%
|
8.66%
|
ROA (Net income/ Total Assets)
|
-
|
2.88%
|
0.15%
|
3.11%
|
4.16%
|
Assets
1 |
-
|
-118
|
-38,000
|
1,897
|
2,740
|
Book Value Per Share
2 |
-
|
19.60
|
17.70
|
21.10
|
23.40
|
Cash Flow per Share
2 |
-
|
1.970
|
0.8200
|
2.400
|
2.710
|
Capex
1 |
-
|
40.3
|
67.5
|
49.3
|
62.7
|
Capex / Sales
|
-
|
1.3%
|
2.34%
|
1.63%
|
1.98%
|
Announcement Date
|
5/15/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
26.38
USD Average target price
34.86
USD Spread / Average Target +32.13% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.41% | 2.36B | | +64.23% | 62.59B | | -2.31% | 41.18B | | +43.79% | 40.29B | | -8.29% | 27.9B | | +11.97% | 26.21B | | -21.16% | 19.09B | | +7.54% | 13.08B | | +27.17% | 12.05B | | +25.72% | 12.26B |
Other Biotechnology & Medical Research
|